Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
9.73 ^USD	-4.33%		+1.88%	+26.69%

04-23	HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	MT
04-09	Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	CI

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology Annual Meeting

February 21, 2024 at 09:32 am

BOSTON - Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.

Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present a poster titled, 'Updated Results from a Phase 1a Trial of STAR-0215 for Hereditary Angioedema' at 3:15pm EST in the Convention Center, Level 2, Hall D, poster number 032.

About Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis.

Contact:

Elizabeth Higgins

Email: investors@astriatx.com

Latest news about Astria Therapeutics, Inc.

HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	04-23	MT
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	04-09	CI
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating	03-26	MT
Transcript : Astria Therapeutics, Inc. - Special Call	03-25
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	03-25	CI
North American Morning Briefing : Markets on Hold -2-	03-20	DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index	03-17	CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	03-15	CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	03-15	CI
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-04	CI
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering	01-30	MT
Astria Therapeutics Files $500 Million Mixed Shelf	12-15	MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating	11-15	MT
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating	11-13	MT
Transcript : Astria Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	11-13
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	11-13	DJ
Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	11-10	CI
Wedbush Adjusts Price Target on Astria Therapeutics to $18 From $25, Maintains Outperform Rating	23-10-13	MT
Transcript : Astria Therapeutics, Inc. - Special Call	23-10-12
HC Wainwright Adjusts Astria Therapeutics Price Target to $18 From $20, Maintains Buy Rating	23-10-12	MT
Indian Equities End Lower on Profit Booking; IT Tops Laggards	23-10-12	MT
Astria Therapeutics Prices Common Stock, Warrants Offering for Expected Gross Proceeds of About $64 Million	23-10-12	MT
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics	23-10-12	MT
Ichnos Sciences Enters Licensing Agreement for Ox40 Antibody Portfolio with Astria Therapeutics	23-10-11	CI

Chart Astria Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-05-16 - Society for Investigative Dermatology Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.73 USD

Average target price

25.29 USD

Spread / Average Target

+159.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASTRIA THERAPEUTICS, INC.	+26.69%	558M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	108B
REGENERON PHARMACEUTICALS, INC.	+10.87%	104B
ARGENX SE	+1.28%	22.33B
BIONTECH SE	-13.14%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-38.36%	17.74B
BEIGENE, LTD.	-10.66%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	14.05B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.51B

Bio Therapeutic Drugs